Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(5.17) per share which missed the analyst consensus estimate of $(2.12) by 143.87 percent. This is a 88.03 percent increase over losses of $(43.20) per
Silexion lost way more money per share than experts thought it would—more than double what people expected. When a company loses more money than predicted, it might mean their plan isn't working as well as hoped, so it's worth watching what they say about fixing things.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.